137 related articles for article (PubMed ID: 2878596)
1. Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function.
Solimon M; Massry SG; Campese VM
Am J Cardiol; 1986 Nov; 58(12):21E-24E. PubMed ID: 2878596
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and concentration--effect relationships of bevantolol (CI-775) in normal volunteers.
McNeil JJ; Drummer OH; Anderson AI; Louis WJ
J Cardiovasc Pharmacol; 1986; 8(6):1201-7. PubMed ID: 2434747
[TBL] [Abstract][Full Text] [Related]
3. Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.
Selen A; Kinkel AW; Darke AC; Greene DS; Welling PG
Eur J Clin Pharmacol; 1986; 30(6):699-704. PubMed ID: 2876899
[TBL] [Abstract][Full Text] [Related]
4. Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure.
Freestone S; McAuslane JA; Prescott LF
Br J Clin Pharmacol; 1991 Oct; 32(4):495-500. PubMed ID: 1958445
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carteolol in relation to renal function.
Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
[TBL] [Abstract][Full Text] [Related]
6. Effects of IGF-I on renal function in end-stage chronic renal failure.
Miller SB; Moulton M; O'Shea M; Hammerman MR
Kidney Int; 1994 Jul; 46(1):201-7. PubMed ID: 7933838
[TBL] [Abstract][Full Text] [Related]
7. Effects of pindolol on renal function II. Effects on intravenous and prolonged oral dosing.
Boner G; Wainer E; Rosenfeld JB
Clin Pharmacol Ther; 1982 Oct; 32(4):423-7. PubMed ID: 7116756
[TBL] [Abstract][Full Text] [Related]
8. Butofilolol pharmacokinetics in chronic renal insufficiency.
Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes.
Farker K; Merkel U; Schweer H; Haerting J; Madani SF; Eggers R; Müller UA; Seyberth HW; Hoffmann A
Eur J Clin Pharmacol; 2002 May; 58(2):85-91. PubMed ID: 12012138
[TBL] [Abstract][Full Text] [Related]
10. Acute renal effects of beta-blockers.
Zech P; Pozet N; Labeeuw M; Laville M; Hadj-Aissa A; Arkouche W; Poncet JF
Am J Nephrol; 1986; 6 Suppl 2():15-9. PubMed ID: 2879466
[TBL] [Abstract][Full Text] [Related]
11. Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.
Vaughan Williams EM
J Clin Pharmacol; 1987 Jul; 27(7):450-60. PubMed ID: 2888789
[TBL] [Abstract][Full Text] [Related]
12. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Fliser D; Bischoff I; Hanses A; Block S; Joest M; Ritz E; Mutschler E
Eur J Clin Pharmacol; 1999 May; 55(3):205-11. PubMed ID: 10379636
[TBL] [Abstract][Full Text] [Related]
13. Renal hemodynamic effects of tertatolol in essential hypertension.
Paillard F; Lantz B; Leviel F; Ardaillou R
Am J Nephrol; 1986; 6 Suppl 2():40-4. PubMed ID: 2879472
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of bevantolol for chronic, stable angina pectoris.
Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
Am J Cardiol; 1986 Nov; 58(12):28E-34E. PubMed ID: 2878598
[TBL] [Abstract][Full Text] [Related]
15. Bevantolol disposition in patients with hepatic cirrhosis.
Nattel S; Lawand S; Matthews C; McCans J
J Clin Pharmacol; 1987 Dec; 27(12):962-6. PubMed ID: 2893814
[TBL] [Abstract][Full Text] [Related]
16. Effects of IGF-I on renal function in patients with chronic renal failure.
O'Shea MH; Miller SB; Hammerman MR
Am J Physiol; 1993 May; 264(5 Pt 2):F917-22. PubMed ID: 8498545
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on disposition of pentopril and its active metabolite.
Rakhit A; Radensky P; Szerlip HM; Kochak GM; Audet PR; Hurley ME; Feldman GM
Clin Pharmacol Ther; 1988 Jul; 44(1):39-48. PubMed ID: 3391004
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
[TBL] [Abstract][Full Text] [Related]
19. Renal tolerance for ioxaglate in patients with chronic renal failure.
Deray G; Cacoub P; Jacquiaud C; Drobinski G; Brillet G; Bunker D; Jaudon MC; Jacobs C
Radiology; 1991 May; 179(2):395-7. PubMed ID: 2014280
[TBL] [Abstract][Full Text] [Related]
20. The effect of celiprolol on glomerular filtration rate and renal blood flow in patients with chronic renal impairment and healthy volunteers.
Robson RA; Bridgman PG; Wells JE; Bailey RR; Lynn KL
Br J Clin Pharmacol; 1992 Apr; 33(4):454-7. PubMed ID: 1349496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
